Tumor 18F-fluorodeoxyglucose (FDG) uptake before treatment, after bevacizumab alone, and after completion of neoadjuvant treatment in the first six patients enrolled in the phase I trial. Bevacizumab alone did not significantly reduce FDG uptake, but the combined treatment produced significant reductions in FDG uptake prior to surgery. PET = positron-emission tomography; SUV = standardized uptake value. Reproduced, with permission, from Willett et al.[58]